US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Gracell Biotechnologies Inc. - American Depositary Shares (NQ:GRCL)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gracell Biotechnologies Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
News headline image
A Preview Of Gracell Biotechnologies's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Gracell Biotechnologies ↗
 
Via Benzinga
News headline image
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
4 Analysts Have This to Say About Gracell Biotechnologies ↗
 
Via Benzinga
News headline image
Preview: Gracell Biotechnologies's Earnings ↗
 
Via Benzinga
News headline image
Bitfarms And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded mixed, with the Dow Jones gaining around 90 points on Friday. Shares of Bitfarms Ltd. (NASDAQ: BITF) shares fell sharply during Friday’s session after the company announced a C$60... 
Via Benzinga
Topics Stocks
News headline image
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023 ↗
 
Via Benzinga
News headline image
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq ↗
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >